Compare Sunrun Inc (RUN) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Sunrun Inc trades at $7.62 (market cap $1.83B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 32.1× Sunrun Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sunrun Inc for 16 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| RUN | TAK | |
|---|---|---|
Market Cap | $1.83B | $58.74B |
Volume | 8,672,852 | 3,110,994 |
Sector | Energy | Health |
52-Week High | $21.41 | $19.05 |
52-Week Low | $7.59 | $13.23 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $16.35B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $7.61, down 2.06% amid broader solar sector weakness. The stock shows bearish technical signals with resistance at $8, while fundamentals reveal mixed results: strong valuation metrics (P/E 5.16, P/S 0.59) contrast with negative operating cash flow and high debt levels. Recent positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.
Despite attractive valuations and analyst optimism (62% buy rating, $16.56 target), RUN faces significant headwinds from high borrowing costs impacting solar financing, weak underlying business trends, and persistent cash burn. The stock presents a high-risk opportunity with substantial upside potential if execution improves, but requires careful monitoring of cash flow stabilization and subscriber growth metrics.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
